Cargando…

Measuring the Permeability of the Blood-Brain Barrier in Alzheimer's Disease Using Dynamic Contrast Enhanced MRI

AIMS: 1) To compare blood brain barrier (BBB) permeability between AD and controls. 2) To examine the relationship between BBB permeability and cognitive decline in AD. 3) To examine the relationship between BBB permeability and peripheral markers of inflammation. METHODS: This pilot study combines...

Descripción completa

Detalles Bibliográficos
Autores principales: McCausland, Beth, Huneke, Nathan, Varatharaj, Aravinthan, Gee, Claire, Kunicki, Amy, Darekar, Angela, Teeling, Jessica, Zetterberg, Henrik, Holmes, Clive, Galea, Ian, Amin, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345320/
http://dx.doi.org/10.1192/bjo.2023.215
_version_ 1785073061136957440
author McCausland, Beth
Huneke, Nathan
Varatharaj, Aravinthan
Gee, Claire
Kunicki, Amy
Darekar, Angela
Teeling, Jessica
Zetterberg, Henrik
Holmes, Clive
Galea, Ian
Amin, Jay
author_facet McCausland, Beth
Huneke, Nathan
Varatharaj, Aravinthan
Gee, Claire
Kunicki, Amy
Darekar, Angela
Teeling, Jessica
Zetterberg, Henrik
Holmes, Clive
Galea, Ian
Amin, Jay
author_sort McCausland, Beth
collection PubMed
description AIMS: 1) To compare blood brain barrier (BBB) permeability between AD and controls. 2) To examine the relationship between BBB permeability and cognitive decline in AD. 3) To examine the relationship between BBB permeability and peripheral markers of inflammation. METHODS: This pilot study combines the use whole brain DCE-MRI, with measures of peripheral inflammation in serum and urine. This is a clinical cohort study with longitudinal and cross-sectional arms, involving n = 15 AD and n = 17 age and gender matched controls. BBB permeability is measured using DCE-MRI and inflammation is measured by comparing serum cytokine and urine neopterin concentrations. AD participants attend three study visits over 12 months; control participants attend two over one week. Urinary neopterin analysis is being conducted in February 2023.The 12 month follow up visits complete in May 2023. Both neopterin and longitudinal cognitive assessment data will be included in the poster presentation in July. RESULTS: AD and control groups were well matched with no significant differences in demographics and multi-morbidity. We measured blood cytokine profiles for IL-6, IL-8, IL-2, IL-4, IL-1b, IL-10, IL13, IL-12p70-, TNF-alpha and INF-gamma. Only INF-Gamma was significantly different; higher in AD vs Controls (mean ± SD; 28.758 ± 90.226 AD, 3.773 ± 2.256 Control, P = 0.03). There were no significant differences in markers of neurodegeneration NfL and pTau-181, or vascular markers VCAM1, ICAM1, CRP and SAA between the groups. Ki is being calculated for overall whole brain, white matter, grey matter and hippocampus regions; an interim analysis showed no significant differences between the tissue categories, but analysis is ongoing. CONCLUSION: There are currently no prognostic biomarkers that accurately predict decline in AD. We believe this pilot study will add to the literature about the utility and feasibility of DCE-MRI to measure BBB permeability. We hope that combining DCE-MRI with blood and urine biomarkers will further our knowledge of the pathophysiology of AD and help to develop minimally invasive biomarkers for identifying patients with AD, including those who are at risk of faster progression.
format Online
Article
Text
id pubmed-10345320
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-103453202023-07-15 Measuring the Permeability of the Blood-Brain Barrier in Alzheimer's Disease Using Dynamic Contrast Enhanced MRI McCausland, Beth Huneke, Nathan Varatharaj, Aravinthan Gee, Claire Kunicki, Amy Darekar, Angela Teeling, Jessica Zetterberg, Henrik Holmes, Clive Galea, Ian Amin, Jay BJPsych Open Research AIMS: 1) To compare blood brain barrier (BBB) permeability between AD and controls. 2) To examine the relationship between BBB permeability and cognitive decline in AD. 3) To examine the relationship between BBB permeability and peripheral markers of inflammation. METHODS: This pilot study combines the use whole brain DCE-MRI, with measures of peripheral inflammation in serum and urine. This is a clinical cohort study with longitudinal and cross-sectional arms, involving n = 15 AD and n = 17 age and gender matched controls. BBB permeability is measured using DCE-MRI and inflammation is measured by comparing serum cytokine and urine neopterin concentrations. AD participants attend three study visits over 12 months; control participants attend two over one week. Urinary neopterin analysis is being conducted in February 2023.The 12 month follow up visits complete in May 2023. Both neopterin and longitudinal cognitive assessment data will be included in the poster presentation in July. RESULTS: AD and control groups were well matched with no significant differences in demographics and multi-morbidity. We measured blood cytokine profiles for IL-6, IL-8, IL-2, IL-4, IL-1b, IL-10, IL13, IL-12p70-, TNF-alpha and INF-gamma. Only INF-Gamma was significantly different; higher in AD vs Controls (mean ± SD; 28.758 ± 90.226 AD, 3.773 ± 2.256 Control, P = 0.03). There were no significant differences in markers of neurodegeneration NfL and pTau-181, or vascular markers VCAM1, ICAM1, CRP and SAA between the groups. Ki is being calculated for overall whole brain, white matter, grey matter and hippocampus regions; an interim analysis showed no significant differences between the tissue categories, but analysis is ongoing. CONCLUSION: There are currently no prognostic biomarkers that accurately predict decline in AD. We believe this pilot study will add to the literature about the utility and feasibility of DCE-MRI to measure BBB permeability. We hope that combining DCE-MRI with blood and urine biomarkers will further our knowledge of the pathophysiology of AD and help to develop minimally invasive biomarkers for identifying patients with AD, including those who are at risk of faster progression. Cambridge University Press 2023-07-07 /pmc/articles/PMC10345320/ http://dx.doi.org/10.1192/bjo.2023.215 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. This does not need to be placed under each abstract, just each page is fine.
spellingShingle Research
McCausland, Beth
Huneke, Nathan
Varatharaj, Aravinthan
Gee, Claire
Kunicki, Amy
Darekar, Angela
Teeling, Jessica
Zetterberg, Henrik
Holmes, Clive
Galea, Ian
Amin, Jay
Measuring the Permeability of the Blood-Brain Barrier in Alzheimer's Disease Using Dynamic Contrast Enhanced MRI
title Measuring the Permeability of the Blood-Brain Barrier in Alzheimer's Disease Using Dynamic Contrast Enhanced MRI
title_full Measuring the Permeability of the Blood-Brain Barrier in Alzheimer's Disease Using Dynamic Contrast Enhanced MRI
title_fullStr Measuring the Permeability of the Blood-Brain Barrier in Alzheimer's Disease Using Dynamic Contrast Enhanced MRI
title_full_unstemmed Measuring the Permeability of the Blood-Brain Barrier in Alzheimer's Disease Using Dynamic Contrast Enhanced MRI
title_short Measuring the Permeability of the Blood-Brain Barrier in Alzheimer's Disease Using Dynamic Contrast Enhanced MRI
title_sort measuring the permeability of the blood-brain barrier in alzheimer's disease using dynamic contrast enhanced mri
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345320/
http://dx.doi.org/10.1192/bjo.2023.215
work_keys_str_mv AT mccauslandbeth measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT hunekenathan measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT varatharajaravinthan measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT geeclaire measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT kunickiamy measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT darekarangela measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT teelingjessica measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT zetterberghenrik measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT holmesclive measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT galeaian measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri
AT aminjay measuringthepermeabilityofthebloodbrainbarrierinalzheimersdiseaseusingdynamiccontrastenhancedmri